{"organizations": [], "uuid": "f1c1708968e8a2ccfa2d1462c2aa8b32a5a5da46", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-merus-and-simcere-announce-strateg/brief-merus-and-simcere-announce-strategic-collaboration-on-multiple-bispecific-antibodies-idUSFWN1P30IT", "country": "US", "domain_rank": 408, "title": "BRIEF-Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T20:08:00.000+02:00", "replies_count": 0, "uuid": "f1c1708968e8a2ccfa2d1462c2aa8b32a5a5da46"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-merus-and-simcere-announce-strateg/brief-merus-and-simcere-announce-strategic-collaboration-on-multiple-bispecific-antibodies-idUSFWN1P30IT", "ord_in_thread": 0, "title": "BRIEF-Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies", "locations": [], "entities": {"persons": [{"name": "merus", "sentiment": "none"}, {"name": "simcere", "sentiment": "none"}], "locations": [{"name": "hk", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "simcere pharmaceutical group", "sentiment": "negative"}, {"name": "merus", "sentiment": "none"}, {"name": "merus nv", "sentiment": "none"}, {"name": "merus nv- co", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Simcere Pharmaceutical Group ( IPO-SMPT.HK ):\n* MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES\n* MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE TO DEVELOP & COMMERCIALIZE IN CHINA 3 BISPECIFIC ANTIBODIES USING COâ€˜S BICLONICS TECHNOLOGY PLATFORM\n* MERUS NV- CO TO BE ELIGIBLE TO GET UPFRONT & MILESTONE PAYMENTS CONTINGENT UPON SIMCERE ACHIEVING CERTAIN SPECIFIED DEVELOPMENT & COMMERCIAL GOALS\n* MERUS NV - MERUS WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION IN CHINA FROM SIMCERE\n* MERUS NV - SIMCERE WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OUTSIDE OF CHINA FROM MERUS\n* MERUS NV - ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSED UNDER COLLABORATION WITH SIMCERE Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:08:00.000+02:00", "crawled": "2018-01-09T17:13:55.028+02:00", "highlightTitle": ""}